News – Page 873 – Endpoints News

Promises made, promises kept: Alnylam CEO John Maraganore adds 3rd straight positive pivotal as he aims at another ...

6 years ago

In crowded prostate cancer market, Pfizer's Xtandi notches third approval for use in earlier stage of disease

6 years ago

What unifies Huntington's, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham's new startup looks to drug ...

6 years ago

GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals ...

6 years ago

FTC to Roche: OK, go ahead and complete your $4.3B Spark buyout — we're convinced now this isn't anticompetitive

6 years ago

Inside Astellas' $3B Audentes gene therapy acquisition: coded messages, a bidding war and $77M for the CEO

6 years ago

Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout

6 years ago

Yet another NASH defeat for Gilead as 3-drug cocktail fizzles. Now one analyst says it's time for a change-up

6 years ago

BioMarin eyes FDA approval as PhIII results emerge in most common form of dwarfism

6 years ago

Wave's Duchenne program comes to a screeching halt — now all eyes will be on Huntington's

6 years ago

Rare skin disease biotech eyes $16 million IPO as trial results come in and cash runs out

6 years ago

BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study

6 years ago

Paul Biondi is jumping from Bristol-Myers to the elite team managing Flagship's startups — with newco plans of his ...

6 years ago

UK antitrust watchdog clears Roche/Spark deal — but what is the FTC thinking?

6 years ago

Going 0-for-4 on a big PhIII program, Novartis scraps their top asthma prospect and signals big trouble for a little ...

6 years ago

Jury finds Gilead liable for $585M and big royalties in Kite CAR-T patent case

6 years ago

Amarin wins a blockbuster approval from the FDA. Now everyone can shift focus to the patent

6 years ago

FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug

6 years ago

Biopharma has abandoned antibiotic development. Here’s why we did, too.

6 years ago

Shehnaaz Suliman dives back into Alzheimer's at Alector; Pyxis recruits SpringWorks founder Lara Sullivan as CEO

6 years ago

More questions than answers for biopharma after UK election; Intercept gets FDA advisory date, and a PDUFA delay

6 years ago

PhII failure in rare neurodegenerative disease? No matter, Biogen will motor on in Alzheimer's

6 years ago

A USPTO legal adviser is off controversial Gilead HIV case after activists allege tweets show bias

6 years ago

Paul Biondi's track record at Bristol-Myers covered billions in deals of every shape and size. Here's the complete ...

6 years ago

First page Previous page 870 871 872873874 875 876 Next page Last page